PNC Financial Services Group’s Astria Therapeutics ATXS Stock Holding History

PNC Financial Services Group’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-443	Closed	-$5.8K	–	5169
2025 Q4	$5.8K	Buy	443 +5	+1%	+$60	﹤0.01%	4170
2025 Q3	$3.19K	Buy	438 +293	+202%	+$1.98K	﹤0.01%	4367
2025 Q2	$777	Buy	+145	New	+$703	﹤0.01%	4603
2025 Q1	–	Sell	-10	Closed	-$89	–	4899
2024 Q4	$89	Buy	+10	New	+$106	﹤0.01%	4713
2019 Q1	–	Sell	-83	Closed	-$2K	–	4021
2018 Q4	$2K	Hold	83	–	–	﹤0.01%	3839
2018 Q3	$4K	Hold	83	–	–	﹤0.01%	3843
2018 Q2	$5K	Hold	83	–	–	﹤0.01%	3828
2018 Q1	$9K	Hold	83	–	–	﹤0.01%	3742
2017 Q4	$7K	Buy	+83	New	+$9.77K	﹤0.01%	3780

PNC Financial Services Group's ATXS Position: Q1 2026 in Review

PNC Financial Services Group sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 443 shares — an estimated $5.8K sold.

PNC Financial Services Group first reported a position in ATXS in Q4 2017 and held it in 9 quarters. The position peaked at $9K in Q1 2018. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

PNC Financial Services Group reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
PNC Financial Services Group sold 443 Astria Therapeutics shares in Q1 2026, an estimated $5.8K.
PNC Financial Services Group first reported a position in Astria Therapeutics in Q4 2017 and held it in 9 quarters.
PNC Financial Services Group's Astria Therapeutics position peaked at $9K in Q1 2018.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.